Novo Nordisk A/SNovo Nordisk is deploying Anthropic's Claude in its drug-research workflow to sharpen biological reasoning and compress idea-to-decision time.

Novo Nordisk has brought Anthropic's Claude into its drug-research workflow, Reuters reported Wednesday, with the U.S. depositary shares trading at $42.125. The diabetes-and-obesity pharmaceutical leader will begin by testing Claude Science on selected scientific questions while also deploying Anthropic models for software-development work. The partnership is aimed at speed rather than AI headlines, with Novo and Anthropic seeking to sharpen biological reasoning and compress the time researchers spend moving from an idea to an actionable scientific decision. No contract value, exclusivity terms, development milestones or quantified savings were disclosed, leaving execution as the real story. Novo produced DKK33.39 billion of adjusted operating profit from DKK78.49 billion of second-quarter sales, implying an adjusted operating margin of roughly 42.5%, while the shares sit at $42.125 against a GF Value estimate of $105.13, leaving the market price 59.93% below that benchmark.
Novo Nordisk A/SNovo Nordisk is deploying Anthropic's Claude in its drug-research workflow to sharpen biological reasoning and compress idea-to-decision time.
Anthropic lands Novo Nordisk as a customer for Claude Science and its models in software development.